Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set - sprookjes - yvandenbroek - TriplyDB

Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set

Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set

http://www.wikidata.org/entity/Q28389579

about

In vitro human cell line models to predict clinical response to anticancer drugs Reconstruction of nuclear receptor network reveals that NR2E3 is a novel upstream regulator of ESR1 in breast cancer Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties Protein kinase Cα promotes cell migration through a PDZ-dependent interaction with its novel substrate discs large homolog 1 (DLG1)Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance, Epidemiology, and End Results-Medicare data, 1998-2007 BAYESIAN SPARSE GRAPHICAL MODELS FOR CLASSIFICATION WITH APPLICATION TO PROTEIN EXPRESSION DATA.Reconstruction of pathway modification induced by nicotinamide using multi-omic network analyses in triple negative breast cancer.Bioinformatic analyses identifies novel protein-coding pharmacogenomic markers associated with paclitaxel sensitivity in NCI60 cancer cell lines.Guidelines for the welfare and use of animals in cancer research.A pan-cancer proteomic perspective on The Cancer Genome Atlas.Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep-2 cancer cells.Coordinated regulation of mitochondrial topoisomerase IB with mitochondrial nuclear encoded genes and MYC.Development of a robust classifier for quality control of reverse-phase protein arrays.A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity.Fluorinated amino-derivatives of the sesquiterpene lactone, parthenolide, as (19)f NMR probes in deuterium-free environments.Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas.c-Myc modulation: a key role in melanoma drug response.Bouvardin is a Radiation Modulator with a Novel Mechanism of Action Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer.Exploring genomic profiles of hepatocellular carcinoma.A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer Glucose starvation induces mutation and lineage-dependent adaptive responses in a large collection of cancer cell lines.An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome.Perspective: Opportunities in recalcitrant, rare and neglected tumors.Cell line modeling for systems medicine in cancers (review).An Efficient Electroporation Protocol for the Genetic Modification of Mammalian Cells.Designing of promiscuous inhibitors against pancreatic cancer cell lines.Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma.ApoCanD: Database of human apoptotic proteins in the context of cancer.BRAFV600E cooperates with PI3K signaling, independent of AKT, to regulate melanoma cell proliferation.Proteins associated with the doubling time of the NCI-60 cancer cell lines.AKT in cancer: new molecular insights and advances in drug development.Next-generation phenotypic screening.The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets.A Strategy to Combine Sample Multiplexing with Targeted Proteomics Assays for High-Throughput Protein Signature Characterization.Establishing a high-throughput and automated cancer cell proliferation panel for oncology lead optimization.Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.

P2860

Q27000665-4F6A4235-6FC1-4539-869B-43332A8A296D Q28114915-E479A812-660F-4E42-836F-DE75BBBCA0AD Q28487333-BF0551A9-9010-4BBE-9906-F41265CFDA14 Q30010216-7B4C4028-4339-43A3-8645-2C31941FC042 Q30744596-0AC8DF9C-DF00-46E2-874A-3A5B7CF8FA64 Q30985471-A346670C-78C1-4882-8806-0A3035B1E96D Q33799624-61452A28-0C9E-4F6E-808C-18E206468059 Q33818738-44D54E18-D55B-4863-B42E-410949BD9D0B Q33903753-E1C9FBBF-06BE-48FC-9D52-4D8BBBAA78D9 Q33944976-0919C4CD-F0E2-4FB0-A596-28C062C68425 Q33962243-C0490CF5-692C-4E07-94B2-F20DC0BFB7A0 Q35174664-B03FB40E-FE81-4467-9D12-86FB5D8D8E9E Q35221345-010D9E7D-4FA4-495F-B9E4-C84E8105D54B Q35471445-7B268365-67EC-44A5-9F18-02E276BDFAE6 Q35581611-D6DA7E0F-1705-4AC3-AB47-53DF7566BA44 Q35889621-23BAD4C0-D008-423A-B45B-68EDDA158780 Q36021891-5C0F7599-8A3B-4817-BD02-DAD4285D6418 Q36213103-DA34E259-D175-45AF-8D7A-3DB699714DE7 Q36274938-AE0DDB0B-FD66-4BD5-9386-39BDF9808084 Q36354855-B07AF886-4017-442B-8A7D-D4E16B1C7588 Q36393332-3C56815A-7A98-4D04-86E6-AC303C8D8AFF Q36490656-C0702A93-D3A0-4E61-BAD6-C9325D4538D2 Q36525420-4B18A6D1-79F8-4161-B555-2FDB52B5878B Q36578468-EDEF2205-A581-4CD7-AE48-9F3DC5FE6BAD Q36919864-2A27458E-7D6C-4C2A-8BCA-A7CFB4E1C2BB Q37197528-A4A3ED2D-1A95-4D56-B4D0-E4E07C645B84 Q37503954-29301542-003D-4405-A2D3-D348F587900D Q37597919-D4A451BD-F31B-483E-9997-1D53FFE3E503 Q37700338-A454ACAC-395C-46E4-B19C-FCE5B6D103F2 Q38148747-B413C384-9C22-446E-ACD3-F076C8E61144 Q38333966-D1C071AE-1F3E-4593-8986-827212350100 Q38520679-EB2EFC20-A639-49C7-892B-65C3C28FC982 Q38601402-DD852648-6E62-458B-8D9F-4F934173468B Q38846044-A13AB797-DC8D-43FA-85E8-A574DBAA1CB8 Q38846991-A7D20E91-F613-44FB-AC4C-540F9894566C Q38880745-94FB860E-6C3F-46C3-ADE9-6669741F36F6 Q38906407-306E2D12-1732-4E2C-896E-584E8EF0066A Q39033381-AAEA17D1-85BA-49A7-9C58-C11FCE7D8BA5 Q39144212-3644D905-CB8C-4BDD-A26A-7B07CACE6F88 Q39224151-1FDAA29A-370B-4080-9A70-AAF71BDDDB33

P2860

Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set

http://www.wikidata.org/entity/Q28389579

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Integrative analysis of proteo ...... he NCI 60 cancer cell line set

@ast

Integrative analysis of proteo ...... he NCI 60 cancer cell line set

@en

Integrative analysis of proteo ...... he NCI 60 cancer cell line set

@nl

type

label

Integrative analysis of proteo ...... he NCI 60 cancer cell line set

@ast

Integrative analysis of proteo ...... he NCI 60 cancer cell line set

@en

Integrative analysis of proteo ...... he NCI 60 cancer cell line set

@nl

prefLabel

Integrative analysis of proteo ...... he NCI 60 cancer cell line set

@ast

Integrative analysis of proteo ...... he NCI 60 cancer cell line set

@en

Integrative analysis of proteo ...... he NCI 60 cancer cell line set

@nl

P1433

Q28389579-CC78AAFE-DE6A-4111-855C-CED689CFB2D4

P1476

Q28389579-CA829D0E-BF8C-487A-BC81-C8838B642ECA

P2093

Q28389579-0C21D860-B136-46B6-93F1-AB9F5B0D4405

Q28389579-3CC2F027-E114-40DD-AAEC-EFBA15F3A793

Q28389579-4AB73B2D-2EE8-4FBF-91EC-4DA257466F61

Q28389579-702E6CE5-7FB9-4699-B200-EA9C81BD7755

Q28389579-85341A74-175C-4214-AB55-C4E8615C77B2

Q28389579-96C44949-CCA6-41D3-B6BA-6116A2110A71

Q28389579-BB524891-E654-4CA8-8300-FC0A1B3F0B39

Q28389579-BEF45C20-1ED7-4270-8BC6-1B72D1F43740

Q28389579-CD22627F-0425-4275-A291-631EBAD32D62

Q28389579-D5718E4B-5D92-4CBB-B000-41BBBBF7D4A9

P2860

Q28389579-01F00600-76A3-45CC-B463-BC780874B2D7

Q28389579-0797F023-2C0A-42D7-8B67-98FE2760A78F

Q28389579-1BE03D53-761C-4F22-920F-E89362B97DA2

Q28389579-1D7860D0-425E-46C7-9CBF-553DDB944E09

Q28389579-2651546C-5F6D-4B12-97FA-DA0BBFCA6E32

Q28389579-2AC6CB5C-F103-47BB-B82D-ABDD21F4B31D

Q28389579-3A51C50D-5E69-4A95-8500-A45A193E6592

Q28389579-3F159020-6490-4664-AEA8-B66B3FD8060F

Q28389579-5872A1FE-B4B2-4AE6-9295-E3F053CBCAB6

Q28389579-59889934-296E-48F6-BABF-FD04C3D1375B

P304

Q28389579-2A967E42-8E27-4532-B4A9-507988CAC4DC

P31

Q28389579-01764419-68AF-443D-B887-DC63D5DA0C73

P356

Q28389579-66E439F4-EE84-4177-B23D-B4D4EB37F22D

P407

Q28389579-D4163CAF-8AF5-4B25-9890-E0FB86C78513

P433

Q28389579-5191231D-AF46-4685-A471-A08FA8C27D87

P478

Q28389579-8F801C12-2DEE-4EDD-B2F1-F610BC375884

P50

Q28389579-712E074C-DD71-4C7E-947C-C74D4B0C2D8B

Q28389579-861B9666-A98F-4227-993D-ED32918DC9D2

Q28389579-E3A8DA11-4795-40F5-A674-02EB41EC1C5C

P577

Q28389579-D644A2AC-69C3-423F-9A2F-0952CE25A11B

P698

Q28389579-D8D92023-6170-40E5-ABD0-1E5AD7A4A804

P932

Q28389579-E4327B3D-03D4-48E7-A921-A8097B86BBC1

P356

1535-7163.MCT-09-0743

P1433

Molecular Cancer Therapeutics

P1476

Integrative analysis of proteo ...... he NCI 60 cancer cell line set

@en

P2093

Bryan T Hennessy

http://www.w3.org/2001/XMLSchema#string

Eun Sung Park

http://www.w3.org/2001/XMLSchema#string

Gordon B Mills

http://www.w3.org/2001/XMLSchema#string

John N Weinstein

http://www.w3.org/2001/XMLSchema#string

Ju-Seog Lee

http://www.w3.org/2001/XMLSchema#string

Mark Carey

http://www.w3.org/2001/XMLSchema#string

Michael A Davies

http://www.w3.org/2001/XMLSchema#string

Rosalia Rabinovsky

http://www.w3.org/2001/XMLSchema#string

Roshan Agarwal

http://www.w3.org/2001/XMLSchema#string

Sang-Bae Kim

http://www.w3.org/2001/XMLSchema#string

P2860

An integrative genomic and proteomic approach to chemosensitivity prediction

Systematic variation in gene expression patterns in human cancer cell lines

The NCI60 human tumour cell line anticancer drug screen

A gene expression database for the molecular pharmacology of cancer

A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery

Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays.

Establishing connections between microarray expression data and chemotherapeutic cancer pharmacology.

Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel.

Synthetic lethal screen identification of chemosensitizer loci in cancer cells.

Gene expression patterns within cell lines are predictive of chemosensitivity.

P304

257-267

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-09-0743

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Levi A Garraway

P577

2010-02-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20124458

http://www.w3.org/2001/XMLSchema#string

P932

4085051

http://www.w3.org/2001/XMLSchema#string